Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Another Administrative Action Taken Against MTPC on Medway Injection; 3rd in 4 Years
October 2, 2013
- US FDA Approves Brintellix for Treatment of MDD in Adults: Takeda, Lundbeck
October 2, 2013
- Asahi Kasei Pharma, Pfizer Japan Strike Copromotion Deal for Recomodulin
October 2, 2013
- Nichi-Iko to Take Over Astellas’s Shizuoka Plant Next April
October 1, 2013
- Takeda Files for Approval of Hib Vaccine in Japan
October 1, 2013
- Amgen Astellas BioPharma to Go on Stream Oct. 1; JV Chief Takahashi Eager to Make It a “Category Leader”
September 30, 2013
- Luseogliflozin in Domestic PIII Study Significantly Reduces HbA1c: Taisho Pharmaceutical
September 27, 2013
- Nippon Shinyaku, Fuji Pharma Launch Lunabell Tablets ULD
September 27, 2013
- Maruho to Turn Maeda Pharmaceutical into Subsidiary, Expand Production Capability
September 26, 2013
- 3 Pharma Groups Demand Permanent Introduction of Premium at CSIMC; Healthcare Rep Still Wary
September 26, 2013
- Merck, NCC Tie Up in Cancer Drug R&D for Asian Patients
September 26, 2013
- Cancer Pain Reliever E-fen Buccal Tablets Launched: Taiho, Teikoku Seiyaku
September 26, 2013
- Daiichi Sankyo Dogged by Renewed Quality Woes at Ranbaxy; FDA Mute on Details
September 26, 2013
- Pfizer Japan’s Termination of CMR Agreement a Setback for Quintiles
September 25, 2013
- 1st ADC Kadcyla Approved for HER2-Positive Breast Cancer: Chugai
September 25, 2013
- Unique Marketing System Jacks Up Profits at Vital KSK; Customer-by-Customer Cost Analyses Lend Support
September 24, 2013
- Sanwa Kagaku, DSP to Terminate Copromotion Deal for Seibule
September 24, 2013
- Sanofi K.K. Launches GLP-1 Receptor Agonist Lyxumia
September 20, 2013
- Eisai’s US Unit to Collaborate with Polish Research Firm Selvita on Anticancer Agents
September 20, 2013
- MTPC Completes Acquisition of Medicago, Now Ready to Bolster Vaccine Development
September 20, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…